Repression of mammalian target of rapamycin complex 1 inhibits intestinal regeneration in acute inflammatory bowel disease models

Journal of Immunology

Volumn 195, Issue 1, 2015, Pages 339-346

  Guan, Yuting ^a   Zhang, Long ^a   Li, Xia ^a   Zhang, Xinyan ^a   Liu, Shijie ^a   Gao, Na ^a   Li, Liang ^a   Gao, Ganglong ^b   Wei, Gaigai ^a   Chen, Zhaohua ^a   Zheng, Yansen ^a   Ma, Xueyun ^a   Siwko, Stefan ^c   Chen, Jin Lian ^b   Liu, Mingyao ^a,c   Li, Dali ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DEXTRAN SULFATE; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; STAT3 PROTEIN; TRINITROBENZENESULFONIC ACID; DODECYL SULFATE SODIUM; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; RHEB PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE CELL; INTESTINE EPITHELIUM CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REGENERATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CACO 2 CELL LINE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HAPLOINSUFFICIENCY; IMMUNOLOGY; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; CACO-2 CELLS; CELL PROLIFERATION; COLITIS; GENE EXPRESSION REGULATION; HAPLOINSUFFICIENCY; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOMERIC GTP-BINDING PROTEINS; MULTIPROTEIN COMPLEXES; NEUROPEPTIDES; SIGNAL TRANSDUCTION; SIROLIMUS; SODIUM DODECYL SULFATE; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TRINITROBENZENESULFONIC ACID;

EID: 84932140804     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303356     Document Type: Article

References (48)

1. Pizarro, T. T., and F. Cominelli. 2007. Cytokine therapy for Crohn's disease: advances in translational research. Annu. Rev. Med. 58: 433-444.
2. Irvine, E. J. 2008. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm. Bowel Dis. 14: 554-565.
3. Ullman, T. A., and S. H. Itzkowitz. 2011. Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816.
4. Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
5. García Rodríguez, L. A., A. Ruigómez, and J. Panés. 2006. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130: 1588-1594.
6. Barker, N., J. H. van Es, J. Kuipers, P. Kujala, M. van den Born, M. Cozijnsen, A. Haegebarth, J. Korving, H. Begthel, P. J. Peters, and H. Clevers. 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
7. van der Flier, L. G., and H. Clevers. 2009. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71: 241-260.
8. Cai, J., N. Zhang, Y. Zheng, R. F. de Wilde, A. Maitra, and D. Pan. 2010. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24: 2383-2388.
9. Shinoda, M., M. Shin-Ya, Y. Naito, T. Kishida, R. Ito, N. Suzuki, H. Yasuda, J. Sakagami, J. Imanishi, K. Kataoka, et al. 2010. Early-stage blocking of Notch signaling inhibits the depletion of goblet cells in dextran sodium sulfate-induced colitis in mice. J. Gastroenterol. 45: 608-617.
10. Koch, S., P. Nava, C. Addis, W. Kim, T. L. Denning, L. Li, C. A. Parkos, and A. Nusrat. 2011. The Wnt antagonist Dkk1 regulates intestinal epithelial homeostasis and wound repair. Gastroenterology 141: 259-268, 268.e1-8.
11. Lees, C. W., W. J. Zacharias, M. Tremelling, C. L. Noble, E. R. Nimmo, A. Tenesa, J. Cornelius, L. Torkvist, J. Kao, S. Farrington, et al. 2008. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med. 5: e239.
12. Liu, S., Y. Qian, L. Li, G. Wei, Y. Guan, H. Pan, X. Guan, L. Zhang, X. Lu, Y. Zhao, et al. 2013. Lgr4 gene deficiency increases susceptibility and severity of dextran sodium sulfate-induced inflammatory bowel disease in mice. J. Biol. Chem. 288: 8794-8803, discussion 8804.
13. Laplante, M., and D. M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293.
14. Bai, X., D. Ma, A. Liu, X. Shen, Q. J. Wang, Y. Liu, and Y. Jiang. 2007. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980.
15. Castro, A. F., J. F. Rebhun, G. J. Clark, and L. A. Quilliam. 2003. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278: 32493-32496.
16. Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17: 1829-1834.
17. Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13: 1259-1268.
18. Lu, Z. H., M. B. Shvartsman, A. Y. Lee, J. M. Shao, M. M. Murray, R. D. Kladney, D. Fan, S. Krajewski, G. G. Chiang, G. B. Mills, and J. M. Arbeit. 2010. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 70: 3287-3298.
19. Mavrakis, K. J., H. Zhu, R. L. Silva, J. R. Mills, J. Teruya-Feldstein, S. W. Lowe, W. Tam, J. Pelletier, and H. G. Wendel. 2008. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22: 2178-2188.
20. Nardella, C., Z. Chen, L. Salmena, A. Carracedo, A. Alimonti, A. Egia, B. Carver, W. Gerald, C. Cordon-Cardo, and P. P. Pandolfi. 2008. Aberrant Rhebmediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22: 2172-2177.
21. Wang, Y., Q. Ding, C. J. Yen, W. Xia, J. G. Izzo, J. Y. Lang, C. W. Li, J. L. Hsu, S. A. Miller, X. Wang, et al. 2012. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21: 374-387.
22. Fujishita, T., K. Aoki, H. A. Lane, M. Aoki, and M. M. Taketo. 2008. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc. Natl. Acad. Sci. USA 105: 13544-13549.
23. Sun, S. Y. 2013. Impact of genetic alterations on mTOR-targeted cancer therapy. Chin. J. Cancer 32: 270-274.
24. Huang, S., M. A. Bjornsti, and P. J. Houghton. 2003. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2: 222-232.
25. Pham, P. T., P. C. Pham, G. M. Danovitch, D. J. Ross, H. A. Gritsch, E. A. Kendrick, J. Singer, T. Shah, and A. H. Wilkinson. 2004. Sirolimusassociated pulmonary toxicity. Transplantation 77: 1215-1220.
26. Wirtz, S., C. Neufert, B. Weigmann, and M. F. Neurath. 2007. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2: 541-546.
27. Goorden, S. M., M. Hoogeveen-Westerveld, C. Cheng, G. M. van Woerden, M. Mozaffari, L. Post, H. J. Duckers, M. Nellist, and Y. Elgersma. 2011. Rheb is essential for murine development. Mol. Cell. Biol. 31: 1672-1678.
28. Weichhart, T., G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T. M. Stulnig, W. H. Hörl, M. Hengstschläger, et al. 2008. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577.
29. Delgoffe, G. M., K. N. Pollizzi, A. T. Waickman, E. Heikamp, D. J. Meyers, M. R. Horton, B. Xiao, P. F. Worley, and J. D. Powell. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12: 295-303.
30. Sancak, Y., L. Bar-Peled, R. Zoncu, A. L. Markhard, S. Nada, and D. M. Sabatini. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290-303.
31. Jewell, J. L., R. C. Russell, and K. L. Guan. 2013. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 14: 133-139.
32. Pickert, G., C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H. A. Lehr, S. Hirth, B. Weigmann, S. Wirtz, et al. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206: 1465-1472.
33. Choi, S. M., J. P. McAleer, M. Zheng, D. A. Pociask, M. H. Kaplan, S. Qin, T. A. Reinhart, and J. K. Kolls. 2013. Innate Stat3-mediated induction of the antimicrobial protein Reg3g is required for host defense against MRSA pneumonia. J. Exp. Med. 210: 551-561.
34. Jin, X., T. A. Zimmers, Z. Zhang, R. H. Pierce, and L. G. Koniaris. 2010. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 59: 186-196.
35. Kim, J. H., J. E. Kim, H. Y. Liu, W. Cao, and J. Chen. 2008. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J. Biol. Chem. 283: 708-715.
36. Araki, K., A. H. Ellebedy, and R. Ahmed. 2011. TOR in the immune system. Curr. Opin. Cell Biol. 23: 707-715.
37. Jiang, Y. P., L. M. Ballou, and R. Z. Lin. 2001. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J. Biol. Chem. 276: 10943-10951.
38. Ban, K., and R. A. Kozar. 2012. Protective role of p70S6K in intestinal ischemia/ reperfusion injury in mice. PLoS One 7: e41584.
39. Fielhaber, J. A., S. F. Carroll, A. B. Dydensborg, M. Shourian, A. Triantafillopoulos, S. Harel, S. N. Hussain, M. Bouchard, S. T. Qureshi, and A. S. Kristof. 2012. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J. Immunol. 188: 4535-4542.
40. Faller, W. J., T. J. Jackson, J. R. Knight, R. A. Ridgway, T. Jamieson, S. A. Karim, C. Jones, S. Radulescu, D. J. Huels, K. B. Myant, et al. 2015. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 517: 497-500.
41. Aoki, K., Y. Tamai, S. Horiike, M. Oshima, and M. M. Taketo. 2003. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat. Genet. 35: 323-330.
42. Shao, J., B. M. Evers, and H. Sheng. 2004. Roles of phosphatidylinositol 39-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 64: 229-235.
43. Thiem, S., T. P. Pierce, M. Palmieri, T. L. Putoczki, M. Buchert, A. Preaudet, R. O. Farid, C. Love, B. Catimel, Z. Lei, et al. 2013. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J. Clin. Invest. 123: 767-781.
44. Faivre, S., G. Kroemer, and E. Raymond. 2006. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5: 671-688.
45. Das, B. B., L. Shoemaker, S. Subramanian, C. Johnsrude, M. Recto, and E. H. Austin. 2007. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J. Heart Lung Transplant. 26: 296-298.
46. McWilliams, T. J., B. J. Levvey, P. A. Russell, D. G. Milne, and G. I. Snell. 2003. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J. Heart Lung Transplant. 22: 210-213.
47. Lieberthal, W., R. Fuhro, C. C. Andry, H. Rennke, V. E. Abernathy, J. S. Koh, R. Valeri, and J. S. Levine. 2001. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am. J. Physiol. Renal Physiol. 281: F693-F706.
48. Fouraschen, S. M., P. E. de Ruiter, J. Kwekkeboom, R. W. de Bruin, G. Kazemier, H. J. Metselaar, H. W. Tilanus, L. J. van der Laan, and J. de Jonge. 2013. mTOR signaling in liver regeneration: rapamycin combined with growth factor treatment. World J. Transplant. 3: 36-47.